HIV T cell vaccines, the importance of clades.
Development of an HIV vaccine presents a formidable challenge. One of the unresolved, yet central issues is the importance of HIV variability. Here we argue that even with the recent focus on the induction of T cell-mediated immunity, HIV vaccines should match the local circulating HIV clades. Whether used alone or in a combination with vaccines eliciting HIV-neutralizing antibodies, efforts must be made to develop a T cell vaccine that stimulates a broad and long-lasting response.
McMichael
Andrew
A
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK. andrew.mcmichael@ndm.ox.ac.uk
Mwau
Matilu
M
Hanke
Tomás
T
D016915:AIDS Vaccines; D000595:Amino Acid Sequence; D000818:Animals; D017951:Antigen Presentation; D000940:Antigenic Variation; D017321:Clinical Trials, Phase I as Topic; D000939:Epitopes / Q000276:immunology; D006678:HIV / Q000145:classification* / Q000235:genetics / Q000276:immunology; D015483:HIV Antibodies / Q000096:biosynthesis; D015488:HIV Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D015658:HIV Infections / Q000453:epidemiology / Q000821:virology; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007156:Immunologic Memory; D007376:Interleukin-2 / Q000276:immunology; D007630:Kenya / Q000453:epidemiology; D008251:Macaca; D051379:Mice; D009500:Neutralization Tests; D013329:Structure-Activity Relationship; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic
D016915:AIDS Vaccines; D000939:Epitopes; D015483:HIV Antibodies; D015488:HIV Antigens; D006680:HLA Antigens; D007376:Interleukin-2; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic